Utility of syngo iFlow in the assessment of Bladder Cancer Treatment

Utility of syngo iFlow in the assessment of Bladder Cancer Treatment - Utility of syngo iFlow in the assessment of Bladder Cancer Treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016327

Enrollment

Registered

2015-01-28

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Interventions

Newly developed bladder preservation therapy for bladder cancer using double balloon-occluded-arterial-infusion (BOAI) of an anticancer agent known as OMC (Osaka Medical College) regimen has allowed 8

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Invasive bladder cancer patients aged 20 years or older

Exclusion criteria

Exclusion criteria: The cases that the catheter could not be placed in the right position. The patients having iodine hypersensitivity.

Design outcomes

Primary

Measure	Time frame
For 30 cases, in BOAI and non-BOAI patterns we analysed the flow of contrast material in the bladder artery, superior gluteal artery, and inferior gluteal artery by using the software, syngo iFlow.	—

Countries

Japan

Contacts

Public ContactKiyohito Yamamoto

Osaka Medical College Department of Radiology

rad105@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026